These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11841348)

  • 1. Fibrinogen-fibrin system regulators from bloodsuckers.
    Zavalova LL; Basanova AV; Baskova IP
    Biochemistry (Mosc); 2002 Jan; 67(1):135-42. PubMed ID: 11841348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance of gammaA/gamma' fibrin clots to fibrinolysis.
    Falls LA; Farrell DH
    J Biol Chem; 1997 May; 272(22):14251-6. PubMed ID: 9162058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibrin(ogen) as a Therapeutic Target: Opportunities and Challenges.
    Gaule TG; Ajjan RA
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34203139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vampire bat salivary plasminogen activator promotes robust lysis of plasma clots in a plasma milieu without causing fluid phase plasminogen activation.
    Hare TR; Gardell SJ
    Thromb Haemost; 1992 Aug; 68(2):165-9. PubMed ID: 1412162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of amyloid-beta (1-42) as a cofactor for plasminogen activation by vampire bat plasminogen activator and recombinant human tissue-type plasminogen activator.
    Kruithof EK; Schleuning WD
    Thromb Haemost; 2004 Sep; 92(3):559-67. PubMed ID: 15351852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of inhibition of fibrinolysis and fibrinogenolysis by the end fibrinogen degradation products.
    Khavkina LS; Rozenfeld MA; Leonova VB
    Thromb Res; 1995 Apr; 78(2):173-87. PubMed ID: 7482434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of fibrinogen carbamylation on fibrin clot formation and stability.
    Binder V; Bergum B; Jaisson S; Gillery P; Scavenius C; Spriet E; Nyhaug AK; Roberts HM; Chapple ILC; Hellvard A; Delaleu N; Mydel P
    Thromb Haemost; 2017 May; 117(5):899-910. PubMed ID: 28382370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A fibrinogen concentrate Haemocomplettan (Riastap) or a Factor XIII concentrate Fibrogammin combined with a mini dose of tranexamic acid can reverse the fibrin instability to fibrinolysis induced by thrombin- or FXa-inhibitor.
    He S; Johnsson H; Zabczyk M; Hultenby K; Cao H; Blombäck M
    Br J Haematol; 2013 Mar; 160(6):806-16. PubMed ID: 23360261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrin selectivity of the isolated protease domains of tissue-type and vampire bat salivary gland plasminogen activators.
    Toschi L; Bringmann P; Petri T; Donner P; Schleuning WD
    Eur J Biochem; 1998 Feb; 252(1):108-12. PubMed ID: 9523718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tridegin, a novel peptidic inhibitor of factor XIIIa from the leech, Haementeria ghilianii, enhances fibrinolysis in vitro.
    Seale L; Finney S; Sawyer RT; Wallis RB
    Thromb Haemost; 1997 May; 77(5):959-63. PubMed ID: 9184410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence for thrombin enhancement of fibrin polymerization that is independent of its catalytic activity.
    Kaminski M; Siebenlist KR; Mosesson MW
    J Lab Clin Med; 1991 Mar; 117(3):218-25. PubMed ID: 2002278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism.
    Reed GL; Houng AK
    Circulation; 1999 Jan; 99(2):299-304. PubMed ID: 9892598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrin clot structure - pro-fibrinolytic effect of oral contraceptives in apparently healthy women.
    Sidelmann JJ; Kluft C; Krug AH; Winkler U; Jespersen J; Gram JB
    Thromb Haemost; 2017 Apr; 117(4):700-705. PubMed ID: 28150855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structure and biological features of fibrinogen and fibrin.
    Mosesson MW; Siebenlist KR; Meh DA
    Ann N Y Acad Sci; 2001; 936():11-30. PubMed ID: 11460466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
    Konieczynska M; Fil K; Bazanek M; Undas A
    Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A hamster antibody to the mouse fibrinogen gamma chain inhibits platelet-fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis.
    Jirousková M; Smyth SS; Kudryk B; Coller BS
    Thromb Haemost; 2001 Oct; 86(4):1047-56. PubMed ID: 11686323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of the basic mechanisms of fibrinogen to fibrin conversion and of fibrinolysis: intravascular coagulation versus primary fibrinolysis.
    Colick JA; Fisher LM
    Va Med Mon (1918); 1970 May; 97(5):310-4 passimass. PubMed ID: 4276992
    [No Abstract]   [Full Text] [Related]  

  • 18. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
    Haskel EJ; Eisenberg PR; Abendschein DR
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding.
    Weitz JI
    J Vasc Interv Radiol; 1995; 6(6 Pt 2 Suppl):19S-23S. PubMed ID: 8770837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors.
    Lenfors S; Gustafsson D
    Semin Thromb Hemost; 1996; 22(4):335-42. PubMed ID: 8944418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.